Breast cancers with simultaneous human epidermal growth factor receptor 2 (HER2) amplification and PIK3CA mutation represent good examples of simultaneous RTK hyperactivity and activation of the PI3K pathway at several levels [100,101]. This evidence concerns the gene PIK3CB and breast carcinoma.